These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 215185)

  • 21. The murine sarcoma virus-induced tumor: exception or general model in tumor immunology?
    Levy JP; Leclerc JC
    Adv Cancer Res; 1977; 24():1-66. PubMed ID: 66859
    [No Abstract]   [Full Text] [Related]  

  • 22. Characterization of effector lymphocytes associated with immunity to murine sarcoma virus (MSV) induced tumors. I. Physical properties of cytolytic T lymphocytes generated in vitro and of their immediate progenitors.
    Plata R; MacDonald HR; Engers HD
    J Immunol; 1976 Jul; 117(1):52-8. PubMed ID: 180182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Rejection of non viral tumors caused by infection with murine sarcoma virus].
    Basombrio MA
    Medicina (B Aires); 1977; 37(2):127-32. PubMed ID: 197370
    [No Abstract]   [Full Text] [Related]  

  • 24. Tumor inhibiting capacity of spleen and lymph node cells from mice with murine sarcoma virus (MSV-M)-induced tumors.
    Weiland E; Mussgay M
    Z Immunitatsforsch Exp Klin Immunol; 1975 Nov; 150(5):414-23. PubMed ID: 181922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of cytotoxic lymphoid spleen cells from STU-mice with Moloney sarcoma by a 3H-proline microcytotoxicity assay.
    Weiland E; Mussgay M
    Med Microbiol Immunol; 1976 Jun; 162(2):81-7. PubMed ID: 1084460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antigenic specificity of the cytolytic T lymphocyte (CTL) response to murine sarcoma virus-induced tumors. II. Analysis of the clonal progeny of CTL precursors stimulated in vitro with syngeneic tumor cells.
    Brunner KT; MacDonald HR; Cerottini JC
    J Immunol; 1980 Apr; 124(4):1627-34. PubMed ID: 6154076
    [No Abstract]   [Full Text] [Related]  

  • 27. Stimulation of mouse migration inhibitory factor (MIF) production form MSV-immune lymphocytes by soluble tumor-associated antigen: requirement for histocompatible macrophages.
    Landolfo S; Herberman RB; Holden HT
    J Immunol; 1977 Apr; 118(4):1244-8. PubMed ID: 191532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of 51Cr release for detecting cell-mediated cytotoxic responses to solid chemically induced rat tumours.
    Zöller M; Price MR; Baldwin RW
    Br J Cancer; 1977 Jun; 35(6):834-43. PubMed ID: 194618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Specificity of 51Cr-release cytotoxicity of lymphocytes immune to murine sarcoma virus.
    Herberman RB; Aoki T; Nunn M; Lavrin DH; Soares N; Gazdar A; Holden H; Chang KS
    J Natl Cancer Inst; 1974 Oct; 53(4):1103-11. PubMed ID: 4139276
    [No Abstract]   [Full Text] [Related]  

  • 30. Primary and secondary in vitro generation of cytolytic T lymphocytes in the murine sarcoma virus system.
    Plata F; Cerottini JC; Brunner KT
    Eur J Immunol; 1975 Apr; 5(4):227-33. PubMed ID: 185057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative in vitro studies on effector cell diversity in the cellular immune response to murine sarcoma virus (MSV)-induced tumors in mice.
    Plata F; Gomard E; Leclerc JC; Levy JP
    J Immunol; 1974 Apr; 112(4):1477-87. PubMed ID: 4360862
    [No Abstract]   [Full Text] [Related]  

  • 32. Murine sarcoma virus pseudotypes used as immunogens against viral and chemical oncogenesis.
    Basombrío MA; Mayer AM; Pasqualini CD
    Cancer Res; 1977 Jun; 37(6):1768-76. PubMed ID: 192461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Standardization of the chromium-51 release, cell-mediated cytotoxicity assay: cryopreservation of mouse effector and target cells.
    Holden HT; Oldham RK; Ortaldo JR; Herberman RB
    J Natl Cancer Inst; 1977 Mar; 58(3):611-22. PubMed ID: 839557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T cell-mediated immunity to oncornavirus-induced tumors. III. Specific and nonspecific suppression in tumor-bearing mice.
    Plater C; Debré P; Leclerc JC
    Eur J Immunol; 1981 Jan; 11(1):39-44. PubMed ID: 6452278
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cell-mediated immunity to antigens associated with murine sarcoma virus-induced tumors: augmentation of cytolytic T lymphocyte activity by successive specific and nonspecific stimulation in vitro.
    Ryser JE; Cerottini JC; Brunner KT
    Eur J Immunol; 1979 Mar; 9(3):179-84. PubMed ID: 221224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The specificity of effector T cells activated by tumours induced by murine oncornaviruses.
    Shellam GR; Knight RA; Mitchison NA; Gorczynski RM; Maoz A
    Transplant Rev; 1976; 29():249-76. PubMed ID: 58459
    [No Abstract]   [Full Text] [Related]  

  • 37. Antigens of tumours induced by naturally occurring murine sarcoma virus (MSV-FBJ). II. Detection of cell-surface antigens by indirect membrane immunofluorescence.
    Jones DB; Moore M
    Br J Cancer; 1974 Feb; 29(2):158-67. PubMed ID: 4133783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional heterogeneity and T cell-dependent activation of macrophages from murine sarcoma virus (MSV)-induced tumors.
    Holden HT; Varesio L; Taniyama T; Puccetti P
    Adv Exp Med Biol; 1979; 121B():509-20. PubMed ID: 232622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of proliferation of lymphoma cells and T lymphocytes by suppressor cells from spleens of tumor-bearing mice.
    Kirchner H; Muchmore AV; Chused TM; Holden HT; Herberman RB
    J Immunol; 1975 Jan; 114(1 Pt 1):206-10. PubMed ID: 122986
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Private specificities of H-2K and H-2D loci as possible selective targets for effector lymphocytes in cell-mediated immunity.
    Brondz BD; Egorov IK; Drizlikh GI
    J Exp Med; 1975 Jan; 141(1):11-26. PubMed ID: 46906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.